Novartis AG NVS NYSE

Novartis AG (NVS) reported total assets of $115.57B and total liabilities of $69.02B for fiscal year 2025, resulting in total equity of $46.55B.

The company held $11.59B in cash and short-term investments. Total debt stood at $37.03B, with net debt of $25.6B. The Debt-to-Equity (D/E) ratio was 0.8 (moderate).

Current ratio is 1.12, suggesting adequate short-term liquidity. Interest coverage is 14.4x (strong).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (94/100) — Total assets $115.57B and equity $46.55B support the company's competitive scale
• VALUE (40/100) — Debt-to-Equity 0.8 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 68/100 with 4/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

RHHBY

Roche Holding AG

$51.02

+0.65%

AZN

AstraZeneca PLC

$204.38

+1.06%

MRK

Merck & Co., Inc.

$119.96

-0.16%

GILD

Gilead Sciences, Inc.

$140.45

+1.02%

PFE

Pfizer Inc.

$27.13

-0.77%